Evidence map›Paper›PMID 19135882›Full record

ArticleCell2009

Who benefits from granulomas, mycobacteria or host?

Tyler D Bold, Joel D Ernst

Open access · bronzeAbstract readComment
In one paragraph

Article in Cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Tuberculosis: The success tale of less explored dormantFrontiers in cellular and infection microbiology · 2022
    Review
  14. Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review.Frontiers in cellular and infection microbiology · 2021
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Cell Biology of Intracellular Adaptation ofMicrobiology spectrum · 2019
    Review
  20. Isoliquiritigenin attenuates spinal tuberculosis through inhibiting immune response in a New Zealand white rabbit model.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Tyler D BoldDepartment of Medicine (Infectious Diseases), New York University Langone Medical Center, New York, NY 10016, USA.
Joel D Ernst
NYU Langone Health · US

Funding

MEDICAL SCIENTIST TRAININGT32GM007308 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PHILIPS, MARK REID · 1985 to 2019
$23.2M
Initiation of the Immune Response to M. tuberculosisR01AI051242 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ERNST, JOEL D. · 2002 to 2019
$8.3M
Mycobacterium tuberculosis evasion of CD4+ T cells in vivoR01AI084041 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ERNST, JOEL D. · 2010 to 2015
$2.3M
NIAID NIH HHS R01 AI051242NIAID NIH HHS R01 AI084041NIGMS NIH HHS T32 GM007308
6 · The paper itself

Abstract

By investigating host-pathogen interactions in zebrafish using intravital imaging, Davis and Ramakrishnan (2009) provide evidence that aggregates of immune cells known as granulomas, long thought to constrain mycobacterial infection, may instead facilitate its spread.

Indexed as

Host-Pathogen InteractionsAnimalsGranulomaMycobacteriumMycobacterium InfectionsZebrafish

Identifiers

PMID19135882
PMCPMC4214211
OpenAlexW2032186524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.